MG Short has questioned the European Patent #1773395. It's a patent that describes how Multikine can manage cholesterol.
"FAKE INFO" he declared!
CEL-SCI has many patents AND don't forget this: The FDA granted Multikine Orphan Drug designation which gives potential for 7 year market exclusivity upon approval. Assuming approval in early 2021, that gets us to 2028!
Yes, CEL-SCI has patent to treat cholesterol with Multikine.
In fact, CEL-SCI issued a Press Release about it. It states Multikine has:
"potential to treat certain patients taking statins without side effects."
Every heard of "Off Label" uses? Why wouldn't CEL-SCI try to patent it and capture more markets? But MG Short will describe it as something devious and nefarious.
It just isn't!
Copyright © 2020 MG-Short - All Rights Reserved.
Visit KillCVMShorts.com for more info